Coeptis Therapeutics, Inc.
General ticker "COEP" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $131.2M (TTM average)
Coeptis Therapeutics, Inc. follows the US Stock Market performance with the rate: 41.0%.
Estimated limits based on current volatility of 4.3%: low 13.27$, high 14.47$
Factors to consider:
- Total employees count: 5 (0.0%) as of 2022
- Current price 30.1% above estimated high
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [4.31$, 13.90$]
- 2025-12-31 to 2026-12-31 estimated range: [2.87$, 9.74$]
Financial Metrics affecting the COEP estimates:
- Positive: with PPE of -8.2 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -34.45 <= 0.04
- Positive: 19.35 < Shareholder equity ratio, % of 35.75 <= 42.53
- Negative: negative Net income
- Positive: Interest expense per share per price, % of 2.05 <= 3.31
Short-term COEP quotes
Long-term COEP plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 |
|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM |
| Operating Expenses | $21.49MM | $10.05MM |
| Operating Income | $-21.49MM | $-10.05MM |
| Non-Operating Income | $0.22MM | $-0.82MM |
| Interest Expense | $0.11MM | $0.40MM |
| R&D Expense | $6.67MM | $2.33MM |
| Income(Loss) | $-21.27MM | $-10.88MM |
| Profit(Loss)* | $-21.27MM | $-10.88MM |
| Stockholders Equity | $4.31MM | $3.19MM |
| Assets | $8.07MM | $8.91MM |
| Operating Cash Flow | $-7.24MM | $-6.65MM |
| Financing Cash Flow | $4.92MM | $5.71MM |
| Earnings Per Share** | $-0.83 | $-5.65 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.